Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Operations: 2012-2024

Historic Cash from Operations for Rocket Pharmaceuticals (RCKT) over the last 13 years, with Dec 2024 value amounting to -$209.7 million.

  • Rocket Pharmaceuticals' Cash from Operations rose 3.23% to -$50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.1 million, marking a year-over-year decrease of 5.20%. This contributed to the annual value of -$209.7 million for FY2024, which is 7.60% down from last year.
  • According to the latest figures from FY2024, Rocket Pharmaceuticals' Cash from Operations is -$209.7 million, which was down 7.60% from -$194.9 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Cash from Operations peaked at -$74.6 million during FY2020, and registered a low of -$209.7 million during FY2024.
  • Over the past 3 years, Rocket Pharmaceuticals' median Cash from Operations value was -$194.9 million (recorded in 2023), while the average stood at -$194.3 million.
  • Data for Rocket Pharmaceuticals' Cash from Operations shows a maximum YoY slumped of 62.33% (in 2021) over the last 5 years.
  • Rocket Pharmaceuticals' Cash from Operations (Yearly) stood at -$74.6 million in 2020, then slumped by 62.33% to -$121.2 million in 2021, then tumbled by 47.03% to -$178.1 million in 2022, then fell by 9.42% to -$194.9 million in 2023, then fell by 7.60% to -$209.7 million in 2024.